Cancer Genetics Investor Deck

January 25, 2017
THE ONCOLOGY
DIAGNOSTICS
PARTNER FROM
BENCH TO BEDSIDE
RedChip Global Online Growth Conference
Nasdaq
(CGIX)

2017 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2
Forward-Looking Statement
These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology,
clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other
statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks of cancellation of customer contracts or
discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights
and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2015 and 10-Q for
the quarter ended September 30, 2016 along with other filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update
these forward-looking statements.

EVERYTHING WE DO AT CGI IS
FOCUSED ON ONE KEY IDEA…
…DELIVER INNOVATION & PATIENT
VALUE BY PROVIDING THE MOST
COMPREHENSIVE CAPABILITIES IN
ONCOLOGY DIAGNOSTICS &
PRECISION MEDICINE

Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030
Global Footprint Created by Highly
Strategic M&A
3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015
Strong & Growing Partnerships with Leading
BioPharma
CONTRACTS WITH 8 of 10 TOP BIOPHARMA
+650% INCREASE WITH BIOPHARMA(1) CUSTOMERS
FROM 2012 TO 2015
Innovation Engine & Expertise Driven By
Key Collaborations
18 RESEARCH COLLABORATIONS WITH
LEADING INSTITUTIONS
Unique, Proprietary Portfolio of Genomic
Tests & Panels
20 COMMERCIALLY LAUNCHED TESTS
49 US PATENTS AND 100+ FOREIGN PATENTS
Diversified & High Growth Revenue Streams 77% Revenue Growth 2014-15 / 43% 4-YEAR CAGR
World-Class Management Team 100+ CUMULATIVE YEARS OF EXPERIENCE
Investor Highlights: Cancer Genetics Addresses
the Trends in Oncology from Bench to Bedside
(1) In signed contracts & potential revenue

Our Mission is to be the Oncology Diagnostics Partner
of Choice from Bench to Bedside
DELIVERING CRITICAL GENOMIC
INSIGHTS TO PHYSICIANS
TO PERSONALIZE TREATMENT
& IMPROVE OUTCOMES
CLINICAL
TRIALS
RESEARCH
PATIENT
CARE
PARTNERING WITH LEADING
RESEARCH INSTITUTIONS TO
DRIVE INNOVATION AND
DEVELOP NEW INSIGHTS
PROVIDING UNPARALLELED
EXPERTISE TO BIOPHARMA
COMPANIES FOR IMPROVED
THERAPEUTIC DEVELOPMENT
INNOVATION & EXECUTION

KEY M&A
CRITERIA
TARGETED
ACQUISITIONS
90,000 SQ. FT.
GLOBAL FOOTPRINT
Response Genetics, Inc. (October 2015)
 Leading solid tumor testing franchise with content in lung, colorectal, skin
and brain cancers as well as FDA-cleared Tissue of Origin Test®
 Strong commercial presence in the Western & Southeastern US with 3,000+
customers
 Established community oncologists & pathologists sales channel
CALIFORNIA
BioServe Biotechnologies, India (August 2014)
 First company to provide DNA synthesis, DNA sequencing & related
services in India
 Customers include leading cancer research institutes (ICMR, CSIR) as well
as major pharmaceutical and biotechnology companies
Gentris, Corp. (July 2014)
 Leading global provider of biopharma, discovery, pharmacogenomics, next-
generation sequencing, genotyping, and biorepository services
 US FDA-compliant lab in Zhanjiang Hi-Tech Park, Shanghai, China
RESPONSE GENETICS
LOS ANGELES, CA
Active and Successful M&A Strategy Focused on Growth,
Capabilities, and Global Footprint
1. Access to Differentiated
Oncology Testing
Capabilities & Content
2. Ability to Expand
Geographic Footprint Into
Key, High Growth Markets
3. Opportunity to Strengthen
& Diversify Customer Base
Across Research,
BioPharma & Clinical End
Markets
4. Ability to Realize
Commercial & Operational
Synergies
5. Shared Cultural Values
Based on Innovation &
Teamwork
BIOSERVE
HYDERABAD
INDIA
GENTRIS
SHANGHAI
CHINANORTH CAROLINA
RTP

The Oncology Marketplace & Opportunity
SPENDING ON ONCOLOGY TESTING
Source: IMS Health MIDAS, Dec. 2014; IMS Health Market Prognosis, March 2015. ISR Reports October 2015 & CGI Analysis
POTENTIAL BUYING CENTERS
Community
Hospitals Regional
Cancer Centers
4,000+ U.S.
HOSPITALS
3,000+
U.S. CLINICAL
TRIALS FOR ALL
CANCER TYPES
Pharmaceutical &
Biotechnology
Companies
200+
RESEARCH
CENTERS
IN THE U.S.
Universities &
Research Centers
85% ONCOLOGY
PATIENTS
Treated in
Community Setting
$42B ~$57B
3.98 4.68
3.72
5.41
0.84
1.02
2015 2020
Clinical
Biopharma
Discovery
$8.5 Bn
$11.2 Bn

Primary Growth Drivers During 2016-17
• Key immuno-markers are
already FDA cleared and
in market: PD-1 & PDL-1
• CGI offers ALL the PD-L1
companion diagnostic
tests available on the
market for immuno-
oncology therapies
• Multiple partnerships in
development
Immuno-Oncology Healthcare Systems
• Need for a partner that
can provide unique tests
along with day-to-day
collaboration for patient
needs
• Increasing clinical and
economic acceptance of
CGI’s focused NGS
Panels (Lymphoma,
Myeloid, Lung, etc.)
Testing Innovation
• Launch of Multiple Myeloma
panel with Mayo Clinic
• More marketing focus and
data on FDA-cleared Tissue
of Origin® and CE-cleared
FHACT® for Cervical Cancer
• Launch of focused, multi-
gene liquid biopsy tests for
lung and renal cancer in
upcoming quarters
Biopharma Partners
• Pharmas need companies
that can provide testing,
innovation and patient
insights
• CGI has both content and
capabilities that are unique
or in high market demand
• In discussions with several
pharma companies for
large scale partnerships

TOTAL REVENUE AND FUTURE GROWTH(1)
(1) Approximate expected future revenues under signed contracts with biotechnology & pharma customers for testing & services to support currently planned clinical trials
Strong and Growing Relationships with Leading
Biopharma Companies
$0.6M
$2.7M
$5.6M
$11.6M
$9.3M
2012 2013 2014 2015 9 months
$4.3M
$6.6M
$10.2M
$18.0M
$19.8MCGI HAS CONTRACTS
WITH TOP BIOPHARMA
COMPANIES
8 of 10
NUMBER OF CLINICAL
TRIALS CGI IS ACTIVELY
SUPPORTING WITH ITS
TESTING, GENOMIC
SERVICES, & BIOMARKER
CAPABILITIES
120+
+$40M
ANTICIPATED
FUTURE
REVENUES
FROM
BIOPHARMA
CUSTOMERS
($ in millions)
2016

CGI COLLABORATIONS DRIVE
INNOVATION AND IMPROVED
PATIENT FOCUS IN
DEVELOPING OUR UNIQUE
PORTFOLIO

Collaborations with World-Renowned Cancer Research
Institutions
Disease Target Collaboration Highlights
Beth Israel Deaconess Medical Ctr DLBCL (Diffuse Large B-Cell Lymphoma) Biomarker-based outcome prediction using Focus::Lymphoma™ and MatBA®-DLBCL
Cleveland Clinic Kidney Cancer Genomic marker validation
Columbia University AML, MDS, and Myeloid Cancers
(Acute Myeloid Leukemia, Myelodysplastic Syndromes)
NGS panel development
Groupe Hospitalier Pitié Salpétriêre, Paris Kidney Cancer Analysis of biomarker variability by array-CGH & NGS
Huntsman Cancer Institute, Univ of Utah Kidney Cancer Evaluation of biomarkers of response using Focus::Renal™ & array-CGH
Kamineni Hospital, India Cervical Cancer FHACT® evaluation
Keck Medicine of USC DLBCL and FL (Follicular Lymphoma) Biomarker investigation
Memorial Sloan-Kettering Cancer Ctr Kidney Cancer Array-CGH & NGS core needle biopsy analyses & biomarkers assoc. w/metastasis
Moffitt Cancer Center CINV and PGx Prediction of side effects associated with chemotherapy (CINV)
National Cancer Institute Cervical Cancer FHACT® development & cervical cancer screening trials
North Shore LIJ Health System CLL/SLL CLL/SLL validation & BTK inhibitor resistance
University of Alabama Central Nervous System Lymphoma Biomarker investigation
University of Iowa Cancer Center DLBCL, Lymphoma MatBA®-DLBCL and Focus::Lymphoma™ validation
Westchester Medical Center Central Nervous System Lymphoma Genomic biomarker identification using UroGenRA®

2016 Collaboration Highlights
H3 Biomedicine Inc. (H3) selected CGI to provide clinical biomarker
services for H3’s lead oncology drug candidate H3B-8800: the first
ever gene splicing anticancer therapeutic agent being developed for
the potential treatment of select blood-based cancers
Announced results at ASCO with HTG, Keck School of Medicine at
USC, and Japan Clinical Cancer Research Organization of using
immune-related genes to identify subtypes of patients associated
with clinical outcome in metastatic colon cancer
Huntsman Cancer Institute at University of Utah, Pfizer, and CGI
entered a collaboration for the validation of CGI’s NGS-based kidney
cancer panel, which includes a signature for the prediction of response
to Sunitinib®, and the development of cell-free DNA assay for disease
monitoring.

Unique, Proprietary Portfolio of Genomic Tests & Panels
RESEARCH &
DISCOVERY
CLINICAL
DEVELOPMENT
COMMERCIAL
DEVELOPMENT
 Provide comprehensive
and technology
agnostic methodologies
 Drive novel discovery
and development
through partnerships
with key thought
leaders
 Target unmet and
critical disease states
 Meaningfully impact
and improve clinical
trials and patient care
MARKET
ENTRY
(1) Pipeline of projects may change based on business or scientific rationale
(2) Joint Venture with the Mayo Clinic
Guiding Principals for
Portfolio Development(1)
MULTIPLE MYELOMA
FOLLICULAR LYMPHOMA
LUNG CANCER
ONCOSPIRE
GENOMICS(2)
BLOOD
CANCERS
MYELOID NGS PANELS [AML; MDS; MPN; OTHER MYELOID MALIGNANCIES] 4 TESTS IN MARKET
MATBA® FOR B-CELL CANCERS [CLL&SLL; DLBCL; FL; MCL] 4 TESTS IN MARKET
LYMPHOMA NGS PANELS [CLL; DLBCL&FL; MCL; OTHER LYMPHOMAS] 5 TESTS IN MARKET
SOLID
TUMORS
TISSUE OF ORIGIN® [FDA-CLEARED] TEST IN MARKET
UROGENRA®-KIDNEY TEST IN MARKET
FHACT® CERVICAL TEST IN MARKET
FOCUS::CANCER HOTSPOT™ [SOLID TUMORS] TEST IN MARKET
FOCUS::ONCOMINE™ [SOLID TUMORS] TEST IN MARKET
FOCUS::RENAL™ TEST IN MARKET
COMPREHENSIVE PHARMACOGENOMICS (PGX) PANEL
HEREDITARY BREAST & OVARIAN CANCER (HBOC) PANELHEREDITARY TEST IN MARKET

OncoSpire Genomics
Joint Venture Between Cancer Genetics & Mayo Clinic
• Joint venture based in Rochester, MN
• Goal: to develop tests that will become the gold standard in
diagnosing and managing patients with selected disease targets
• Diseases with known clinical dilemmas were selected and informed by
clinicians in the Mayo Clinic network
• OncoSpire has the rights to druggable targets that are discovered
PROJECT PIPELINE(1):
~115,000
NEW CASES
PER YEAR
GLOBAL
MULTIPLE MYELOMA
LUNG CANCER
FOLLICULAR LYMPHOMA
~1.8M
NEW CASES
PER YEAR
GLOBAL
RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY
Commercially Launching
~130,000
NEW CASES
PER YEAR
GLOBAL
(1) Pipeline of projects may change based on business or scientific rationale

 Design & Architecture
220 genes & coding regions [~1MB comprising 4,048 tiled regions]
CLIA-approved (April 2016)
Risk / Outcome &
Cell of Origin
Clinical Targets
Associated with
Drug Pathways
BCR/PI3K/WNT
Located within
Aberration
(DLBCL Only)
ABCA13 BIRC3 CDKN2B EPHA7 HIST1H1C JAK2 NFKBIB PIK3CG RAF1 SYK
ABCA3 BLK CIITA ERBB3 HIST1H1E KDM6B NLGN2 PIK3R1 RAPGEF1 SYNJ2
ABCC4 BLNK CNOT6L ETS1 HIST1H2BC KDR NLK PIK3R2 RB1 TBL1XR1
ABCC9 BRAF COL16A1 EZH2 HIST1H3B KIT NOTCH1 PIKFYVE RGS4 TCF4
ABL1 BRD4 CREBBP FAS HIST1H4I KLHL6 NOTCH2 PIM1 RHOA TEC
ACTB BTG1 CSMD3 FAT2 HIST2H2BE KRAS NOX4 PLCB1 ROBO2 TET2
ACTN1 BTG2 CSNK1D FAT4 HRAS LRP1 NR3C1 PLCB4 ROCK2 TLR2
ADAM10 BTK CTBP2 FBXO11 ID3 LRP6 NRAS PLCD1 ROS1 TMEM30A
AHR CARD10 CTNNA2 FGFR1 IGSF1 LRRC7 NTRK1 PLCD3 RRAGC TNF
AKT CARD11 DCC FLT1 IKBKB LYST TENM4 PLCE1 S1PR2 TNFAIP3
APC CARM1 DCP1B FOXO1 IKZF1 MALT1 OGDHL PLCG2 SALL3 TNFRSF11A
APC2 CCND1 DDX21 FOXP1 IKZF3 MAP2K1 P2RX5 PLCZ1 SEMA6C TNFRSF14
AQR CCND3 DGKZ FYN INPP5B MED12 P2RY8 POT1 SF3B1 TNIK
ARID1A CD22 DHDH GCC2 IRF4 MEF2B PARP1 POU2AF1 SGK1 TNRC6B
ATM CD36 DLC1 GNA13 IRF8 MLL2 PDCD1 POU2F2 SI TP53
ATP11C CD58 DSEL GNAI2 ITGB3 MLL3 PDGFRA PRDM1 SLC17A6 TRAF2
ATP6AP1 CD70 DTX1 GPR112 ITPK1 MLLT6 PDK1 PRKCA SLC30A4 TRIM8
B2M CD79A DUSP2 GRB2 ITPKB MRGPRF PIK3AP1 PRKCB SMARCA4 UBR5
BAP1 CD79B DUSP27 GRIN2A ITPR1 MTOR PIK3C2A PRKDC SOCS1 VAV1
BCL10 CDIPT EBF1 GSK3B ITPR1 MYC PIK3C2G PTEN SP140 WHSC1
BCL2 CDK4 EIF2AK4 HCK ITPR2 MYD88 PIK3C3 PTPN13 STAT3 XPO1
BCL6 CDKN2A EP300 HIST1H1B JAK1 NFKBIA PIK3CD PYHIN1 STAT6 ZMYM3

 Design & Architecture
ABL1 CARD11 ERBB2 JAK2 PCNA RBAK STAG2
AFF1 CCDC120 FGFR1 KDM5C PDGFRB-- RHEB TET2
AKT1 CCND2 FLT3 KIT PGLYRP3 ROS1 TNC
AKT2 CDH4 FYN MAGEC1 PIK3CA SCARB2 TP53
ALK CUL1 GLI3 MAPK14 PIK3CG SETD2 TSC1
ARID1A-- DAXX GOLGA5 MET PTCH1 SFXN4 TSC2
AXL DFNA5 GUSB MTOR PTEN SMO UBE2D1
BAP1 DIO2 HIF1A NDRG1 RAF1 SMOX VHL
BMPR1B DST HSP90AA1 NPNT RALGAPA1 SOX4 ZFPM2
BRAF EGFR IFNB1 PBRM1 RAPGEF1 SPRED1 ZNF800
BRINP2 EPHB4 ING4 PCK1 RASSF2 SRC
Renal Extended™ [76 genes] and Focus::Renal™ [32 genes]
rs7121 (GNAS1) rs11549465 (HIF1A) rs1126647 (IL8) rs4073 (IL8)
rs11762213 (MET) rs699947 (VEGFA) rs9582036 (VEGFR1)
Focus::Renal™
NGS Panel [32 genes]
Frequently
Mutated Genes
=
FDA-Approved
Drug Targets
=
Key:
3. GENOME-WIDE GAIN/LOSS ASSESSMENT
1. GENE MUTATION ASSESSMENT
2. PROGNOSTIC SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS)
Diagnosis,
Prognosis,
& Therapy
Response
Renal Cell
Carcinoma
(RCC)

CGI OPERATES AT THE
FOREFRONT OF THE ERA
WHERE GENOMIC AND
IMMUNE MARKERS WILL
ENABLE PRECISION MEDICINE

Our Three Pillars of Innovation
HIGH SENSITIVITY
LIQUID BIOPSY AND
CELL-FREE ANALYSIS
• Portfolio Updates
Anticipated launch of focused, multi-gene liquid biopsy tests for lung
and renal cancer in upcoming quarters
• Oncomine™ Lung cfDNA Assay
Detection levels down to 0.1% with 90% sensitivity & >98% specificity
for point mutations and indels using only a single blood sample
UNIQUE CONTENT
VIA PARTNERSHIPS
& COLLABORATIONS
• Mayo Clinic
Oncospire Genomics joint venture targeting hematological cancers
• Columbia University
Genomic signatures for myelodysplastic syndromes and AML
• Huntsman Cancer Center
Patient response to kidney cancer frontline therapies
IMMUNO-ONCOLOGY
CAPABILITIES THAT ARE
INDUSTRY LEADING
• HTG Collaboration
Expression of genes implicated in patient immune responses to tumors
• Dako / Ventana CDx
Dako 22C3 and Ventana SP263 CDx test for KEYTRUDA®
• Unique Immuno-Oncology Panel via Flow Cytometry
Commercialization of Comprehensive IO Panel via Flow Cytometry
3
2
1

Immuno-Oncology: Greater Insights Require Integrated
Information From Multiple Technologies
AND HAS THE
POTENTIAL TO
IMPACT UP TO 60%
BY 2024,
IMMUNO-ONCOLOGY
DRUG SALES ARE
EXPECTED TO REACH
$35B
OF ALL
CANCER
PATIENTS
Source: IMS Health
IMMUNOPHENOTYPING
& FLOW CYTOMETRY
TRANSCRIPTOME PROFILING
& SEQUENCING VIA NGS
IMMUNOHISTOCHEMISTRY
(IHC)
to assess immune response
against cancers
to measure expression
levels of drug targets
to detect critical biomarkers
such as PD-L1 [FDA-APPROVED]
CANCER
GENETICS’
EXTENSIVE
APPROACH
IN IMMUNO-
ONCOLOGY:
CANCER GENETICS is
listed by MERCK as a
National Reference
Lab for KEYTRUDA® -
a drug that will be
impacting $7.8 BN IN
SALES BY 2025

Combinations of Targeted & Immuno-Oncology Drugs Will
Improve Outcomes and Drive Biomarker Testing
Expected Combination Regimen
Launches in Oncology
4 8 7 7
13
19
15
34
0
10
20
30
40
2014 2015 2016 2017 2018 2019 2020 2021+
 Many combinations will launch over the
next five years with an inflection point
near 2020-2021
 Hematology and breast combos will
continue to dominate through 2018
 After 2018, solid tumor combos will
increase dramatically – especially for
lung cancer and melanoma
 Combinations will incorporate targeted
and immuno-oncology agents and are
likely to have an additive or synergistic
therapeutic effect
Sources: CenterWatch, FDA, clinicaltrials.gov, IMS R&D LifeCycle, IMSCG Analysis,
Cell 161 April 9, 2015 Elsevier Inc.
Time
PercentSurvival
Possibility for Improved Overall Survival
as a Result of Combination Therapy
Chemotherapy Immune Checkpoint Therapy
Genomically
Targeted Therapy
Combination with Genomically Targeted
Agent and Immune Checkpoint Therapy

Targeted Clinical Trials Drive Revenue Today and
Market Share in the Future
REVENUE TODAY FOR BIOPHARMA SERVICES FUTURE REVENUE IN CLINICAL CARE
TODAY FUTURE
>15
MIGHT TRANSFORM CANCER CARE
BASED ON CGI’S ESTIMATE OF A
15% APPROVAL RATE 3-5
POTENTIAL COMPANION DX
TO ACCELERATE CLINICAL
GROWTH & PROFITABILITY
CLINICAL TRIALS WITH CGI
120+

Application
Submitted
Term Through 2022
Term Through 2023
Term Through 2027
Term Through 2030
Term Through 2030
Term Through 2031
2 US Patents | EU | India | Canada
Mature B-Cell Neoplasms
4 US Patents
Tissue of Origin
2 US Patents | EU
Renal Cortical Neoplasms
13 US Patents | PCT | AU | CA | China | Japan
Gene Expression
2 US Patents | Canada
Chromosomal Analysis Using FISH
2 US Applications Filed | PCT
Gynecological Cancers & Precancers
3 US Patents | PCT
HPV-Associated Cancers
Disease-Focused Patent Portfolio: 100+ Global Patents
SELECT SIGNIFICANT PATENTS INCLUDE:

Strong Record of Continuous Growth
FULL YEAR TOTAL REVENUE BY YEAR / CATEGORY
($ IN MILLIONS)
BIOPHARMA
CLINICAL
DISCOVERY
OTHER
2012 2013 2014 2015 9 mos
2016
$4.3M
$6.6M
$10.2M
$18.0M
Q3 TOTAL REVENUE BY YEAR / CATEGORY
($ IN MILLIONS)
Q3 2013 Q3 2014 Q3 2015 Q3 2016
$1.7M
$3.2M
$4.0M
$6.8M
$19.8M
BIOPHARMA
CLINICAL
DISCOVERY
OTHER

Cancer Genetics Summary Statement of Operations
SUMMARIZED INCOME STATEMENTS (dollars in thousands)
SUMMARIZED BALANCE SHEET (dollars in thousands)
Q3 2015 Q2 2016 Q3 2016
REVENUE $4,001 $7,000 $6,750
Gross Profit 898 2,716 2,306
Gross Margin (%) 22% 39% 34%
Research & Development 1,802 1,680 1,594
Sales & Marketing 1,243 1,379 1,054
General & Administrative 3,487 3,658 3,701
OPERATING PROFIT (Loss) ($5,634) ($4,001) ($4,043)
NET INCOME (Loss) ($5,212) ($4,028) ($3,745)
Actual 09/30/16
CASH & CASH EQUIVALENTS $10,716
STOCKHOLDERS’ EQUITY $27,847

FULL YEAR 2015 - $5.7M
CGI PAYMENT HISTORY
(CLINICAL REVENUES ONLY)
COVERED LIVES REPRESENTED BY AGREEMENTS
WITH NATIONAL INTEGRATED NETWORKS
MORE THAN
180M
Clinical Reimbursement Mix & Payer Coverage
Q3 2016 - $2.7M
CGI PAYMENT HISTORY
(CLINICAL REVENUES ONLY)
29%
39%FY 2015
REGIONAL
AND NATIONAL
PAYERS
MEDICARE
COMMERCIAL
PAYERS
32%
DIRECT BILL 14%
52%Q2 2016
REGIONAL
AND NATIONAL
PAYERS
MEDICARE
COMMERCIAL
PAYERS
34%
DIRECT BILL

Growth & Revenue Drivers - Portfolio
CGI is working on a number of initiatives that will add accelerated growth to our core
business that include additions to the portfolio, new partnerships and additional
service offerings
1. Launch of Hereditary Cancer Testing Panel, initially HBOC Q1
• Expect reimbursement in the range of $700 to $2,000 per test
• Major pharma has already ordered 200+ tests
2. Launch of Multiple Myeloma NGS Panel with Mayo Clinic Q2
• Expect reimbursement in the range of $700 to $2,000 per test
• Already in usage by 2 major pharma companies
• In discussions to develop into a focused complementary Dx for monitoring
3. Launch of IO focused NGS Panel for Biopharma Studies Q1
• Awarded one deal that will take place in India and US with IVD company
• Discussions for another deal for an IO panel on NGS with major pharma
4. Launch of Liquid Biopsy for Lung Cancer Profiling Q2 & Q3
5. Launch of Liquid Biopsy for Kidney Cancer Q2 & Q3
ITEM TIMEFRAME

CGIX Has Multiple Points of Strategic Advantage & Are
Leading to Long-Term, Differentiated & Durable Value
MoatsofDifferentiation-SeparatingfromthePack
Comprehensive
Cancer Testing
Portfolio
 Blood Cancers
 Solid Tumors
 Hereditary
 Multiple
Technologies
Oncology
Partner
of Choice
 Provide both
testing and
disease
management
programs based
on informatics
 Become a
collaborative,
trusted partner
of pharma with
upside
Global
Infrastructure
 Secure broader
reach through
partnerships and
select acquisitions
 Invest in
operational
improvements
and IT to achieve
seamless global
operations
Collaborative
Innovation
Engine
 Access to 20+
leading oncology
focused
institutions and
research groups
to lower cost of
development and
create new IP
and tests
Disease
Focused
Knowledge
 Targeting
specific
cancers
provides both
depth and
efficiency of
coverage
Our strategy is to further accelerate our significant competitive
differentiators through operations and also marketing and
collaborative awareness with customers

WORKING TOGETHER
TOWARDS BUILDING A HIGHLY
DURABLE LEADER IN
ONCOLOGY AND PRECISION
MEDICINE

Board of Directors
Panna Sharma
 CEO & president of Cancer Genetics
 General Manager of OncoSpire Genomics
 Previously managing partner/founder of TSG Partners
 70+ buy & sell-side transactions (healthcare companies)
Raju S.K. Chaganti, PhD
 Founded CGI & served as Chairman until 2014
 Internat’ly recognized leader in molecular genetics
 Co-discovered lymphoma & kidney cancer patents
 Incumbent of the William Snee E. Chair at MSKCC
John Pappajohn Non-Executive Chairman
 Involved in 100+ start-up companies
 Served as director of 40+ public companies
 Currently on boards of: American CareSource
Holdings; ConMed Healthcare Mgmt; CNS Response
Howard McLeod, PharmD g
 Personalized Medicine Medical Director at Moffitt
 Founding Director of the Univ. of NC Institute for
Pharmacogenomics (PGx) & Individualized Therapy
 475+ peer-reviewed papers (PGx, applied therapeutics)
Michael J. Welsh, MD c, g
 Investigator at the Howard Hughes Medical Inst.
 Roy J. Carver Biomed Research Chair in Internal
Medicine & Molecular Physiology & Biophysics
 Director of Univ. of Iowa Inst. for Biomed Discovery
Geoffrey Harris, CFA a
 30+ years experience as healthcare analyst & portfolio
manager for biotech/life sci companies
 Portfolio manager/managing partner at c7 Advisors
 Previously: Cantor Fitzgerald; Gleacher & Company
Ted Cannon a,c
 Founder & President of the Clinical Research Center of
Cape Cod
 Previously at Franey Medical Labs; Pharmacia
Diagnostics; Alletess
Franklyn Prendergast, MD, PhD a, c, g
 Director of Mayo Clinic for Individualized Medicine (Retired)
 Currently on boards of: Translational Genomics
Research Inst.; Infectious Disease Research Inst.;
DemeRx, Inc.; Ativa; Eli Lilly & Co.
a: Audit Committee c: Compensation Committee g: Governance and Nominating Committee

Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030
Global Footprint Created by Highly
Strategic M&A
3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015
Strong & Growing Partnerships with Leading
BioPharma
CONTRACTS WITH 8 of 10 TOP BIOPHARMA
+650% INCREASE WITH BIOPHARMA(1) CUSTOMERS
FROM 2012 TO 2015
Innovation Engine & Expertise Driven By
Key Collaborations
18 RESEARCH COLLABORATIONS WITH
LEADING INSTITUTIONS
Unique, Proprietary Portfolio of Genomic
Tests & Panels
20 COMMERCIALLY LAUNCHED TESTS
49 US PATENTS AND 100+ FOREIGN PATENTS
Diversified & High Growth Revenue Streams 77% Revenue Growth 2014-15 / 43% 4-YEAR CAGR
World-Class Management Team 100+ CUMULATIVE YEARS OF EXPERIENCE
Investor Highlights: Cancer Genetics Addresses
the Trends in Oncology from Bench to Bedside
(1) In signed contracts & potential revenue

Thank you Nasdaq
(CGIX)
For further information, please contact us at contact@cgix.com
CGI Headquarters
201 Route 17 North
Rutherford, NJ 07070
Phone: +1 201-528-9200
RUTHERFORD, NJ
Research Triangle Park
133 Southcenter Court
Morrisville, NC 27569
Phone: +1 919-465-0100
RALEIGH, NC LOS ANGELES, CA
1640 Marengo Street
Fourth Floor
Los Angeles, CA 90033
Phone: +1 323-224-3900
#3-1-135/1A CNR Complex
Mallapur Main Road, R.R. Dst.
Hyderabad – 500 076, Telangana
Toll-free: +91 040-2717-8178
HYDERABAD, INDIA
781 Cai Lun Road, Room 803
Shanghai 201203
P.R. China
Toll-free: +86 21-5049-5700
SHANGHAI, CHINA

Cancer Genetics Investor Deck

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (20)

Ähnlich wie Cancer Genetics Investor Deck

Ähnlich wie Cancer Genetics Investor Deck (20)

Mehr von RedChip Companies, Inc.

Mehr von RedChip Companies, Inc. (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Cancer Genetics Investor Deck